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Table S1: Distribution of the number SNP failures per sample, by treatment
and trial
0 1-5 6-10 11+
ALL 917 (82.8%) 145 (13.1%) 20 (1.8%) 25 (2.3%)
ALL: CASE 317 (77.9%) 62 (15.2%) 15 (3.7%) 13 (3.2%)
ALL: CONTROL 600 (85.7%) 83 (11.9%) 5 (0.7%) 12 (1.7%)
IBIS-I 717 (87.5%) 80 (9.8%) 5 (0.6%) 17 (2.1%)
IBIS-I: CASE 230 (87.5%) 26 (9.9%) 1 (0.4%) 6 (2.3%)
IBIS-I: CONTROL 487 (87.6%) 54 (9.7%) 4 (0.7%) 11 (2.0%)
MARSDEN 200 (69.4%) 65 (22.6%) 15 (5.2%) 8 (2.8%)
MARSDEN: CASE 87 (60.4%) 36 (25.0%) 14 (9.7%) 7 (4.9%)
MARSDEN: CASE (TISSUE) 1 (2.6%) 20 (51.3%) 12 (30.8%) 6 (15.4%)
MARSDEN: CASE (BLOOD) 86 (81.9%) 16 (15.2%) 2 (1.9%) 1 (1.0%)
MARSDEN: CONTROL 113 (78.5%) 29 (20.1%) 1 (0.7%) 1 (0.7%)
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Table S2: Sample characteristics by trial. BMI: body mass index; Cont: Control; ER: estrogen-receptor; FDR: number of affected
first-degree relatives; IQR: inter-quartile range; OR: odds ratio; TC: Tyrer-Cuzick model.
Factor Value IBIS (Case) IBIS (Cont) P (IBIS) Mars (Case) Mars (Cont) P (Mars)
Total 256 532 103 104
Treatment Placebo 158 321 56 56
Tamoxifen 98 211 47 48
ER Status Positive 192 393 73 73
Negative 45 97 19 20
Unknown 19 42 11 11
Age(y) Median (IQR) 50 (46-54) 50 (46-54) 0.9 48 (44-54) 48 (44-54) 0.7
Age menarche (y) <12 56 (22%) 129 (24%) 0.9 25 (25%) 23 (22%) 0.9
12 51 (20%) 89 (17%) 16 (16%) 16 (15%)
>12 145 (58%) 309 (59%) 61 (60%) 65 (62%)
Unknown 4 5 1 0
Nulliparious Parous 42 (16%) 71 (13%) 0.31 19 (18%) 14 (13%) 0.41
Age first (IQR) 23.0 (21.0-27.0) 24.0 (21.0-26.0) 0.7 25.0 (21.0-28.0) 26.0 (22.0-28.0) 0.9
Unknown 6 10 0 0
Menopause Pre 127 (50%) 254 (48%) 0.32 61 (59%) 51 (49%) 0.043
Peri 11 ( 4%) 19 ( 4%) 7 ( 7%) 8 ( 8%)
Post 118 (46%) 259 (49%) 35 (34%) 45 (43%)
BMI (kg/m2) Median (IQR) 26.4 (23.3-29.1) 25.8 (23.4-29.9) 0.6 23.1 (22.0-26.6) 23.4 (21.5-26.3) 0.46
Unknown 5 7 6 1
FDR 0 35 (14%) 51 (10%) 0.37 4 ( 4%) 4 ( 4%) 1.0
1 181 (71%) 401 (75%) 80 (78%) 81 (78%)
>1 40 (16%) 80 (15%) 19 (18%) 19 (18%)
TC OR Median (IQR) 2.41 (1.89-3.03) 2.16 (1.76-2.71) <0.001 2.63 (2.10-3.28) 2.39 (1.96-3.24) 0.11
SNP88 Median(IQR) 1.13 (0.82-1.58) 0.99 (0.70-1.39) <0.001 1.13 (0.81-1.70) 1.08 (0.84-1.41) 0.6
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Table S3: Number of failures by SNP.
SNP Chr Position Case Control All
rs616488 1 10566215 3 (0.8%) 0 (0.0%) 3 (0.3%)
rs11249433 1 121280613 1 (0.3%) 0 (0.0%) 1 (0.1%)
rs12405132 1 145644984 2 (0.6%) 0 (0.0%) 2 (0.2%)
rs12048493 1 149906413 0 (0.0%) 1 (0.2%) 1 (0.1%)
rs72755295 1 242034263 3 (0.8%) 5 (0.8%) 8 (0.8%)
rs11552449 1 114448389 0 (0.0%) 1 (0.2%) 1 (0.1%)
rs4245739 1 204518842 0 (0.0%) 0 (0.0%) 0 (0.0%)
rs1045485 2 202149589 0 (0.0%) 0 (0.0%) 0 (0.0%)
rs16857609 2 218296508 0 (0.0%) 0 (0.0%) 0 (0.0%)
rs12710696 2 19320803 0 (0.0%) 0 (0.0%) 0 (0.0%)
rs13387042 2 217905832 1 (0.3%) 0 (0.0%) 1 (0.1%)
rs1550623 2 174212894 2 (0.6%) 0 (0.0%) 2 (0.2%)
rs2016394 2 172972971 0 (0.0%) 1 (0.2%) 1 (0.1%)
rs4849887 2 121245122 0 (0.0%) 0 (0.0%) 0 (0.0%)
rs12493607 3 30682939 0 (0.0%) 0 (0.0%) 0 (0.0%)
rs6796502 3 46866866 0 (0.0%) 1 (0.2%) 1 (0.1%)
rs6762644 3 4742276 2 (0.6%) 1 (0.2%) 3 (0.3%)
rs1053338 3 63967900 0 (0.0%) 2 (0.3%) 2 (0.2%)
rs4973768 3 27416013 1 (0.3%) 1 (0.2%) 2 (0.2%)
rs6828523 4 175846426 0 (0.0%) 0 (0.0%) 0 (0.0%)
rs9790517 4 106084778 0 (0.0%) 0 (0.0%) 0 (0.0%)
rs1432679 5 158244083 1 (0.3%) 1 (0.2%) 2 (0.2%)
rs13162653 5 16186489 0 (0.0%) 1 (0.2%) 1 (0.1%)
rs2012709 5 32567732 0 (0.0%) 0 (0.0%) 0 (0.0%)
rs10472076 5 58184061 0 (0.0%) 0 (0.0%) 0 (0.0%)
rs1353747 5 58337481 2 (0.6%) 1 (0.2%) 3 (0.3%)
rs7707921 5 81538046 1 (0.3%) 3 (0.5%) 4 (0.4%)
rs10069690 5 1279790 1 (0.3%) 0 (0.0%) 1 (0.1%)
rs10941679 5 44706498 1 (0.3%) 0 (0.0%) 1 (0.1%)
rs2736108 5 1297488 0 (0.0%) 1 (0.2%) 1 (0.1%)
rs889312 5 56031884 0 (0.0%) 1 (0.2%) 1 (0.1%)
rs204247 6 13722523 3 (0.8%) 2 (0.3%) 5 (0.5%)
rs9257408 6 28916252 0 (0.0%) 0 (0.0%) 0 (0.0%)
rs11242675 6 1318878 0 (0.0%) 0 (0.0%) 0 (0.0%)
rs12662670 6 151918856 0 (0.0%) 0 (0.0%) 0 (0.0%)
rs2046210 6 151948366 0 (0.0%) 0 (0.0%) 0 (0.0%)
rs4593472 7 130667121 0 (0.0%) 1 (0.2%) 1 (0.1%)
rs720475 7 144074929 0 (0.0%) 0 (0.0%) 0 (0.0%)
rs6964587 7 91630620 0 (0.0%) 1 (0.2%) 1 (0.1%)
rs13267382 8 117209548 0 (0.0%) 1 (0.2%) 1 (0.1%)
rs9693444 8 29509616 0 (0.0%) 0 (0.0%) 0 (0.0%)
rs13365225 8 36858483 2 (0.6%) 0 (0.0%) 2 (0.2%)
rs6472903 8 76230301 1 (0.3%) 0 (0.0%) 1 (0.1%)
rs11780156 8 129194641 0 (0.0%) 1 (0.2%) 1 (0.1%)
rs13281615 8 128355618 1 (0.3%) 3 (0.5%) 4 (0.4%)
rs2943559 8 76417937 0 (0.0%) 1 (0.2%) 1 (0.1%)
rs1011970 9 22062134 2 (0.6%) 1 (0.2%) 3 (0.3%)
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rs10759243 9 110306115 1 (0.3%) 0 (0.0%) 1 (0.1%)
rs865686 9 110888478 1 (0.3%) 0 (0.0%) 1 (0.1%)
rs7904519 10 114773927 2 (0.6%) 3 (0.5%) 5 (0.5%)
rs11814448 10 22315843 0 (0.0%) 0 (0.0%) 0 (0.0%)
rs10995190 10 64278682 1 (0.3%) 0 (0.0%) 1 (0.1%)
rs704010 10 80841148 0 (0.0%) 1 (0.2%) 1 (0.1%)
rs11199914 10 123093901 2 (0.6%) 3 (0.5%) 5 (0.5%)
rs2380205 10 5886734 0 (0.0%) 3 (0.5%) 3 (0.3%)
rs2981579 10 123337335 0 (0.0%) 0 (0.0%) 0 (0.0%)
rs7072776 10 22032942 1 (0.3%) 1 (0.2%) 2 (0.2%)
rs11820646 11 129461171 0 (0.0%) 0 (0.0%) 0 (0.0%)
rs3817198 11 1909006 1 (0.3%) 2 (0.3%) 3 (0.3%)
rs3903072 11 65583066 1 (0.3%) 2 (0.3%) 3 (0.3%)
rs554219 11 69331642 0 (0.0%) 1 (0.2%) 1 (0.1%)
rs75915166 11 69379161 1 (0.3%) 1 (0.2%) 2 (0.2%)
rs12422552 12 14413931 2 (0.6%) 2 (0.3%) 4 (0.4%)
rs10771399 12 28155080 2 (0.6%) 0 (0.0%) 2 (0.2%)
rs17356907 12 96027759 0 (0.0%) 0 (0.0%) 0 (0.0%)
rs1292011 12 115836522 0 (0.0%) 2 (0.3%) 2 (0.2%)
rs11571833 13 32972626 0 (0.0%) 2 (0.3%) 2 (0.2%)
rs2236007 14 37132769 9 (2.5%) 19 (3.0%) 28 (2.8%)
rs941764 14 91841069 0 (0.0%) 2 (0.3%) 2 (0.2%)
rs11627032 14 93104072 3 (0.8%) 0 (0.0%) 3 (0.3%)
rs2588809 14 68660428 0 (0.0%) 0 (0.0%) 0 (0.0%)
rs999737 14 69034682 0 (0.0%) 1 (0.2%) 1 (0.1%)
rs17817449 16 53813367 1 (0.3%) 0 (0.0%) 1 (0.1%)
rs11075995 16 53855291 0 (0.0%) 0 (0.0%) 0 (0.0%)
rs13329835 16 80650805 1 (0.3%) 2 (0.3%) 3 (0.3%)
rs3803662 16 52586341 0 (0.0%) 0 (0.0%) 0 (0.0%)
chr17:29230520:D 17 29166302 1 (0.3%) 0 (0.0%) 1 (0.1%)
rs6504950 17 53056471 0 (0.0%) 0 (0.0%) 0 (0.0%)
rs745571 17 77781387 0 (0.0%) 0 (0.0%) 0 (0.0%)
rs527616 18 24337424 0 (0.0%) 2 (0.3%) 2 (0.2%)
rs1436904 18 24570667 1 (0.3%) 1 (0.2%) 2 (0.2%)
rs6507583 18 42399590 0 (0.0%) 0 (0.0%) 0 (0.0%)
rs2363956 19 17394124 1 (0.3%) 1 (0.2%) 2 (0.2%)
rs3760982 19 44286513 0 (0.0%) 1 (0.2%) 1 (0.1%)
rs4808801 19 18571141 19 (5.3%) 38 (6.0%) 57 (5.7%)
rs8170 19 17389704 3 (0.8%) 1 (0.2%) 4 (0.4%)
rs2823093 21 16520832 1 (0.3%) 0 (0.0%) 1 (0.1%)
rs6001930 22 40876234 1 (0.3%) 0 (0.0%) 1 (0.1%)
rs132390 22 29621477 0 (0.0%) 0 (0.0%) 0 (0.0%)
rs17879961 22 29121087 0 (0.0%) 0 (0.0%) 0 (0.0%)
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Table S4: Summary statistics for each SNP. MAF is the minor allele
frequency from the data. COGS estimates used to form the SNP
score are also given for comparison. HWE tests based on the num-
ber of homozygotes, where the observed number of homozygotes











rs616488 1 31 35 33 1.23 0.94(0.92-0.96) 0.98 1.01
rs11249433 1 46 41 40 0.83 1.09(1.07-1.12) 0.98 1.05
rs12405132 1 36 38 36 1.04 0.95(0.93-0.97) 0.99 1.00
rs12048493 1 42 41 41 0.96 1.06(1.04-1.07) 0.93 1.05
rs72755295 1 4 4 3 0.83 1.16(1.1-1.22) 1.00 1.00
rs11552449 1 17 14 16 0.77 1.07(1.04-1.09) 1.01 1.01
rs4245739 1 27 25 26 0.92 1.03(1.01-1.05) 0.97 0.93
rs1045485 2 12 12 13 1.03 0.97(0.94-1) 0.99 0.99
rs16857609 2 27 29 26 1.15 1.08(1.06-1.11) 1.04 1.04
rs12710696 2 37 40 36 1.14 1.04(1.02-1.06) 1.02 1.03
rs13387042 2 48 47 49 0.98 0.88(0.86-0.9) 1.00 1.01
rs1550623 2 15 15 16 0.96 0.95(0.92-0.97) 0.97 0.95
rs2016394 2 45 45 48 1.01 0.95(0.94-0.97) 1.03 0.99
rs4849887 2 9 8 10 0.93 0.91(0.88-0.94) 1.00 0.98
rs12493607 3 33 33 34 1.04 1.06(1.04-1.08) 0.98 1.01
rs6796502 3 10 8 9 0.88 0.92(0.89-0.95) 0.99 1.01
rs6762644 3 41 42 40 1.07 1.07(1.05-1.09) 0.95 1.08
rs1053338 3 14 14 13 1.11 1.08(1.05-1.11) 0.98 0.99
rs4973768 3 47 48 47 1.08 1.10(1.08-1.12) 1.04 1.03
rs6828523 4 11 10 12 0.97 0.90(0.87-0.93) 1.01 1.01
rs9790517 4 19 19 22 1.02 1.05(1.03-1.08) 1.00 1.02
rs1432679 5 47 48 43 1.06 1.07(1.05-1.09) 0.99 1.06
rs13162653 5 42 45 45 1.14 0.94(0.92-0.96) 1.00 0.95
rs2012709 5 46 46 46 0.99 1.05(1.04-1.07) 1.00 0.97
rs10472076 5 38 40 38 1.05 1.05(1.03-1.07) 1.06 0.98
rs1353747 5 10 8 10 0.74 0.92(0.89-0.95) 0.99 1.00
rs7707921 5 25 26 23 1.05 0.93(0.91-0.95) 1.05 0.98
rs10069690 5 26 28 26 1.07 1.06(1.04-1.09) 1.01 0.95
rs10941679 5 26 27 25 1.03 1.12(1.1-1.15) 0.99 0.98
rs2736108 5 29 30 29 1.05 0.94(0.92-0.96) 1.00 0.94
rs889312 5 29 28 28 0.96 1.12(1.1-1.15) 1.01 1.08
rs204247 6 43 44 44 1.09 1.05(1.03-1.07) 0.99 0.98
rs9257408 6 40 40 41 1.04 1.05(1.03-1.07) 1.06 0.91
rs11242675 6 37 38 38 1.04 0.96(0.94-0.98) 0.98 1.04
rs12662670 6 9 10 7 1.02 1.17(1.13-1.22) 1.02 0.98
rs2046210 6 36 38 34 1.07 1.08(1.06-1.1) 1.05 0.94
rs4593472 7 35 34 35 0.99 0.95(0.93-0.96) 1.04 0.95
rs720475 7 29 23 25 0.72 0.94(0.92-0.96) 1.01 0.96
rs6964587 7 39 40 39 1.10 1.05(1.03-1.07) 0.96 0.98
rs13267382 8 34 38 36 1.20 1.05(1.03-1.07) 0.99 0.98
rs9693444 8 33 34 32 1.06 1.07(1.05-1.09) 1.03 1.05
rs13365225 8 15 16 17 1.07 0.94(0.91-0.96) 1.00 1.00
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rs6472903 8 15 16 18 1.07 0.91(0.89-0.93) 0.99 1.00
rs11780156 8 20 17 16 0.82 1.07(1.04-1.09) 1.01 0.95
rs13281615 8 42 46 40 1.12 1.10(1.08-1.12) 1.00 1.01
rs2943559 8 10 8 7 0.79 1.13(1.09-1.17) 1.00 1.00
rs1011970 9 18 18 17 1.01 1.06(1.03-1.08) 1.02 1.01
rs10759243 9 29 28 29 0.89 1.05(1.03-1.08) 1.04 1.03
rs865686 9 36 33 38 0.90 0.90(0.88-0.92) 0.97 1.00
rs7904519 10 47 47 46 1.00 1.05(1.03-1.07) 0.97 0.97
rs11814448 10 2 2 2 0.92 1.27(1.19-1.36) 1.00 1.00
rs10995190 10 13 10 16 0.80 0.86(0.83-0.88) 1.01 1.01
rs704010 10 40 43 38 1.13 1.08(1.06-1.1) 0.99 1.07
rs11199914 10 32 32 32 0.99 0.95(0.93-0.97) 1.05 0.96
rs2380205 10 44 42 44 0.91 0.99(0.97-1.01) 0.95 0.92
rs2981579 10 44 47 40 1.13 1.27(1.24-1.29) 1.01 1.07
rs7072776 10 28 28 29 1.01 1.07(1.05-1.09) 0.96 1.03
rs11820646 11 41 38 41 0.88 0.95(0.93-0.97) 1.01 0.92
rs3817198 11 34 36 31 1.11 1.07(1.05-1.09) 0.96 0.96
rs3903072 11 45 46 47 1.04 0.95(0.93-0.97) 1.04 1.05
rs554219 11 13 15 12 1.18 1.26(1.23-1.3) 0.99 0.99
rs75915166 11 6 7 6 1.16 1.31(1.26-1.36) 0.99 1.00
rs12422552 12 27 29 26 1.11 1.04(1.02-1.07) 1.00 0.97
rs10771399 12 12 9 12 0.75 0.86(0.83-0.89) 0.99 0.98
rs17356907 12 28 27 30 0.97 0.91(0.9-0.93) 0.96 1.06
rs1292011 12 42 39 42 0.85 0.92(0.9-0.94) 0.93 1.03
rs11571833 13 2 2 1 1.01 1.27(1.15-1.4) 1.00 1.00
rs2236007 14 22 21 21 1.00 0.93(0.91-0.95) 0.98 1.00
rs941764 14 35 37 34 1.16 1.07(1.05-1.09) 0.97 0.99
rs11627032 14 26 26 27 1.03 0.94(0.92-0.96) 1.02 0.99
rs2588809 14 16 14 16 0.90 1.08(1.05-1.11) 1.02 0.99
rs999737 14 24 22 23 0.88 0.92(0.9-0.94) 0.99 0.98
rs17817449 16 41 36 40 0.81 0.93(0.91-0.95) 1.04 0.91
rs11075995 16 23 23 24 1.02 1.04(1.02-1.06) 1.00 0.98
rs13329835 16 21 24 22 1.19 1.08(1.06-1.11) 0.99 1.02
rs3803662 16 31 33 26 1.08 1.24(1.21-1.26) 0.96 1.00
chr17:29230520:D 17 26 24 27 0.94 0.95(0.93-0.97) 0.99 0.98
rs6504950 17 25 28 28 1.19 0.94(0.92-0.96) 0.97 0.96
rs745571 17 49 47 50 0.91 1.05(1.04-1.07) 1.03 1.08
rs527616 18 35 35 38 0.97 0.95(0.93-0.97) 1.02 0.92
rs1436904 18 40 38 40 0.89 0.96(0.94-0.97) 1.01 0.93
rs6507583 18 8 7 7 0.90 0.91(0.88-0.94) 1.00 1.00
rs2363956 19 49 47 49 0.92 1.03(1.01-1.05) 0.99 1.00
rs3760982 19 50 49 46 0.99 1.05(1.03-1.07) 0.99 1.06
rs4808801 19 36 35 35 0.98 0.93(0.91-0.94) 1.02 1.01
rs8170 19 18 19 19 1.09 1.04(1.02-1.07) 1.04 1.03
rs2823093 21 27 27 27 0.96 0.93(0.91-0.95) 1.00 0.95
rs6001930 22 10 12 11 1.16 1.12(1.09-1.16) 1.03 0.99
rs132390 22 4 4 4 0.98 1.14(1.08-1.2) 1.00 1.00
rs17879961 22 0 0 0 1.41 1.37(1.21-1.55) 1.00 1.00
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Table S5: Calibration coefficients from conditional logistic regression model on
log odds of each predictor.
Group Predictor Calibration (95% CI)
Overall SNP88 46% ( 19 to 74%)
TC 71% ( 37 to 106%)
IBIS-I SNP88 56% ( 24 to 87%)
TC 77% ( 38 to 116%)
Marsden SNP88 14% (-43 to 71%)
TC 55% (-13 to 123%)
Placebo SNP88 54% ( 18 to 90%)
TC 79% ( 36 to 123%)
Tamoxifen SNP88 36% ( -7 to 78%)
TC 59% ( 4 to 114%)
ER+ SNP88 56% ( 23 to 88%)
TC 60% ( 21 to 99%)
ER- SNP88 -2% (-62 to 59%)
TC 112% ( 34 to 190%)
Table S6: Observed and expected number of cancers by 10-year risk group decile,
in the placebo arm. SE, standard error; χ2, the chi-squared statistic component
used in a Hosmer-Lemeshow test.
Decile Observed Expected SE χ2
1 24 19.6 4.3 1.1
2 34 23.9 4.7 4.6
3 32 28.5 5.0 0.5
4 26 30.1 5.2 0.6
5 38 32.3 5.4 1.1
6 31 35.9 5.6 0.8
7 41 37.1 5.7 0.5
8 31 42.6 6.0 3.7
9 42 47.9 6.4 0.8
10 64 63.5 7.1 0.0
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Table S7: Additional interaction subgroup tests for the SNP score.
Comparison P
Age Per year 0.49
Menopause status Pre and Peri vs Post 1.0
BMI kg/m2 0.49
Nulliparous Children / not 0.47
Age at first birth Per year 0.19
Age at menarche Per year 0.39
TC family history only Odds ratio 0.7
TC All Odds ratio 0.6
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Table S8: Main results, using SNP score with imputed SNP values where miss-
ing.
Result IQ-OR 95% CI LR-χ2 P mC mC 95% CI
SNP88 1.40 1.15 - 1.70 11.8 <0.001 0.58 0.53 - 0.62
IBIS 1.46 1.19 - 1.79 13.4 <0.001 0.59 0.54 - 0.64
MARSDEN 1.10 0.72 - 1.66 0.2 0.7 0.53 0.43 - 0.62
- Het. (trial) 0.18
TC 1.45 1.21 - 1.73 17.6 <0.001 0.55 0.51 - 0.60
TC x SNP88 (df=1) 1.64 1.36 - 1.98 29.6 <0.001 0.61 0.56 - 0.65
∆χ21 = 13.1 <0.001
SNP88 subgroups
ER+ 1.50 1.19 - 1.87 12.8 <0.001 0.59 0.53 - 0.64
ER- 0.95 0.57 - 1.61 0.0 0.9 0.51 0.40 - 0.62
- Het. (ER) 0.071
Placebo 1.54 1.19 - 2.00 10.9 <0.001 0.61 0.55 - 0.66
Tamoxifen 1.22 0.93 - 1.61 2.1 0.15 0.53 0.46 - 0.60
- Het. (treatment) 0.27
Placebo, ER+ 1.51 1.13 - 2.01 8.0 0.005 0.60 0.54 - 0.67
Placebo, ER- 1.38 0.63 - 3.01 0.7 0.41 0.58 0.44 - 0.73
- Het. (placebo:ER) 0.7
Tamoxifen, ER+ 1.47 1.03 - 2.09 4.8 0.028 0.56 0.48 - 0.65
Tamoxifen, ER- 0.72 0.39 - 1.36 1.0 0.31 0.44 0.28 - 0.60
- Het. (tamoxifen:ER) 0.048
TC subgroups
ER+ 1.33 1.10 - 1.60 9.2 0.002 0.55 0.49 - 0.60
ER- 1.94 1.22 - 3.07 8.8 0.003 0.59 0.49 - 0.68
- Het. (ER) 0.23
Placebo 1.54 1.21 - 1.96 13.3 <0.001 0.55 0.49 - 0.61
Tamoxifen 1.31 1.02 - 1.68 4.6 0.032 0.56 0.50 - 0.63
- Het. (treatment) 0.6
IBIS-I 1.44 1.19 - 1.73 15.3 <0.001 0.55 0.50 - 0.60
MARSDEN 1.28 0.94 - 1.73 2.6 0.11 0.56 0.47 - 0.66
- Het. (trial) 0.6
TC x SNP88 subgroups
ER+ 1.64 1.33 - 2.01 23.5 <0.001 0.60 0.55 - 0.66
ER- 1.56 0.95 - 2.54 3.2 0.072 0.59 0.48 - 0.71
Placebo 1.84 1.43 - 2.38 24.6 <0.001 0.63 0.58 - 0.69
Tamoxifen 1.42 1.08 - 1.87 6.4 0.011 0.57 0.50 - 0.65
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Table S9: Main results, including tissue samples from Marsden controls and
matching cases.
Result IQ-OR 95% CI LR-χ2 P mC mC 95% CI
SNP88 1.38 1.15 - 1.65 12.9 <0.001 0.55 0.51 - 0.60
IBIS 1.45 1.17 - 1.78 12.6 <0.001 0.57 0.52 - 0.62
MARSDEN 1.21 0.86 - 1.70 1.2 0.28 0.51 0.43 - 0.59
- Het. (trial) 0.36
TC 1.48 1.24 - 1.75 20.8 <0.001 0.56 0.52 - 0.60
TC x SNP88 (df=1) 1.67 1.40 - 2.01 33.9 <0.001 0.60 0.56 - 0.65
∆χ21 = 14.7 <0.001
SNP88 subgroups
ER+ 1.43 1.17 - 1.75 12.5 <0.001 0.56 0.51 - 0.61
ER- 1.06 0.69 - 1.64 0.1 0.8 0.52 0.42 - 0.62
- Het. (ER) 0.16
Placebo 1.48 1.16 - 1.88 10.4 0.001 0.58 0.52 - 0.63
Tamoxifen 1.26 0.97 - 1.62 3.1 0.078 0.52 0.45 - 0.60
- Het. (treatment) 0.46
Placebo, ER+ 1.43 1.10 - 1.86 7.2 0.007 0.57 0.50 - 0.63
Placebo, ER- 1.38 0.70 - 2.71 0.9 0.35 0.58 0.44 - 0.71
- Het. (placebo:ER) 0.8
Tamoxifen, ER+ 1.42 1.04 - 1.92 5.3 0.022 0.55 0.47 - 0.63
Tamoxifen, ER- 0.88 0.52 - 1.48 0.2 0.6 0.46 0.31 - 0.61
- Het. (tamoxifen:ER) 0.10
TC subgroups
ER+ 1.36 1.14 - 1.63 11.8 <0.001 0.56 0.50 - 0.61
ER- 1.97 1.23 - 3.15 8.9 0.003 0.59 0.49 - 0.68
- Het. (ER) 0.34
Placebo 1.56 1.24 - 1.97 15.0 <0.001 0.55 0.49 - 0.61
Tamoxifen 1.36 1.06 - 1.75 6.0 0.014 0.57 0.51 - 0.64
- Het. (treatment) 0.7
IBIS-I 1.44 1.19 - 1.73 15.3 <0.001 0.55 0.50 - 0.60
MARSDEN 1.39 1.05 - 1.84 5.5 0.019 0.58 0.50 - 0.66
- Het. (trial) 0.9
TC x SNP88 subgroups
ER+ 1.66 1.36 - 2.04 26.0 <0.001 0.60 0.55 - 0.65
ER- 1.63 1.03 - 2.57 4.6 0.032 0.58 0.47 - 0.68
Placebo 1.81 1.43 - 2.31 25.9 <0.001 0.63 0.57 - 0.68
Tamoxifen 1.47 1.13 - 1.92 8.9 0.003 0.57 0.50 - 0.64
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